Krishna Institute of Medical Sciences Intrinsic Value

Krishna Institute of Medical Sciences intrinsic value. Krishna Institute of Medical Sciences (KIMS) median intrinsic value is ₹450.00 from 9 valuation models (range ₹230–₹1460), vs current price ₹767.80 — -41.4% downside (Trading Above Calculated Value), margin of safety -70.6%. For current market price and key ratios, visit KIMS share price screener.

Market Price (CMP)
₹767.80
Primary Intrinsic Value
₹230.34
Market Cap
₹6142 Cr
-41.4% Downside
Median Value
₹450.00
Value Range
₹230 - ₹1460
Assessment
Trading Above Calculated Value
Safety Margin
-70.6%

KIMS Valuation Methods Summary — DCF, Graham Number & P/E

Krishna Institute of Medical Sciences intrinsic value across 9 models vs current price ₹767.80 — upside/downside and value range per method. Browse KIMS income statement for revenue, profit, balance sheet and cash flow data.

Method Type Intrinsic Value Range Upside/Downside Details
P/E Based Valuation earnings ₹230.34 ₹184.27 - ₹276.41 -70.0% EPS: ₹7.16, Sector P/E: 22x
Book Value Method asset ₹639.75 ₹575.77 - ₹703.73 -16.7% Book Value/Share: ₹319.88, P/B: 2.0x
Revenue Multiple Method revenue ₹1376.00 ₹1238.40 - ₹1513.60 +79.2% Revenue/Share: ₹688.00, P/S: 2.0x
EBITDA Multiple Method earnings ₹1460.00 ₹1314.00 - ₹1606.00 +90.2% EBITDA: ₹1168.00Cr, EV/EBITDA: 10x
Simple DCF (5Y) dcf ₹777.51 ₹622.01 - ₹933.01 +1.3% CF Growth: 12.1%, Discount: 15%
PEG Ratio Method growth ₹230.34 ₹207.31 - ₹253.37 -70.0% EPS Growth: 8.0%, Fair P/E: 6.4x
Growth Adjusted P/E growth ₹230.34 ₹207.31 - ₹253.37 -70.0% Revenue Growth: 6.0%, Adj P/E: 15.5x
ROE Based Valuation profitability ₹450.00 ₹405.00 - ₹495.00 -41.4% ROE: 11.7%, P/E Multiple: 12x
Graham Defensive Method conservative ₹230.34 ₹207.31 - ₹253.37 -70.0% EPS: ₹7.16, BVPS: ₹319.88
Method Types: Earnings Asset DCF Growth Dividend Conservative

KIMS Intrinsic Value vs Market Price — All Valuation Models

Krishna Institute of Medical Sciences fair value range ₹230–₹1460 vs current market price ₹767.80 across 9 valuation models. Analyse KIMS FII DII holdings to track promoter, FII and institutional holdings.

KIMS Intrinsic Value Analysis — Undervalued or Overvalued?

Krishna Institute of Medical Sciences median intrinsic value ₹450.00, current price ₹767.80 — Trading Above Calculated Value by 41.4%, margin of safety -70.6%.

What is the intrinsic value of KIMS?

Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Krishna Institute of Medical Sciences (KIMS) is ₹450.00 (median value). With the current market price of ₹767.80, this represents a -41.4% variance from our estimated fair value.

The valuation range spans from ₹230.34 to ₹1460.00, indicating ₹230.34 - ₹1460.00.

Is KIMS undervalued or overvalued?

Based on our multi-method analysis, Krishna Institute of Medical Sciences (KIMS) appears to be trading above calculated value by approximately 41.4%.

KIMS Financial Health — Key Ratios vs Industry Benchmarks

Krishna Institute of Medical Sciences financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.

Financial Metric Current Value Industry Benchmark Assessment Impact on Valuation
Return on Equity 11.7% Industry Standard: 15%+ Above 10% Measures shareholder return efficiency
Operating Margin 19.0% Industry Standard: 20%+ Above 10% Indicates operational efficiency level
Asset Turnover Ratio 0.71x Industry Standard: 1.0x+ Above 0.5x Measures asset utilization efficiency

KIMS Cash Flow Quality — Operating & Free Cash Flow

Krishna Institute of Medical Sciences operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.

Period Operating Cash Flow Free Cash Flow Cash Flow Quality Sustainability Score
March 2026 ₹511 Cr ₹-215 Cr Positive Operating Cash Flow 6/10
March 2025 ₹582 Cr ₹24 Cr Positive Free Cash Flow 7/10
March 2024 ₹521 Cr ₹145 Cr Positive Free Cash Flow 7/10
March 2023 ₹432 Cr ₹224 Cr Positive Free Cash Flow 8/10
March 2022 ₹324 Cr ₹118 Cr Positive Free Cash Flow 7/10